Intelligent telemonitoring: Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.
Telemonitoring: Telemonitoring using CGM, insulin pen data, and Fitbit data
Study summary
The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for three months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision-support algorithms in the management of insulin treatment.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adults ≥ 18 years.
* Diagnosis of T2D for at least 12 months prior to the day of screening.
* Patients who are being treated with insulin or about to start insulin treatment (insulin naïve) willing to travel to trial site in North Denmark to attend in-person visits.
* Have internet at home, have MitID, and willingness to use a smartphone and the other devices used in the trial
* Signed informed consent.
* Ability to understand and read Danish.
Exclusion Criteria:
* Pregnancy or breastfeeding.
* Major surgery is planned during the trial period.
* Cancer diagnosis within five years prior to inclusion.
* Participation in other interventional trials.
* Limited literacy affecting the use of trial devices.
* Patient who has worn a CGM monitor less than 6 months prior to the trial.
* Terms that, in the opinion of the sub-investigator or investigator, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participate.
* Patients treated with mixed insulin.
Primary outcome measure(s)
CGM time in range — At baseline to three months after randomization Change in CGM time in range (3,9-10,0 mmol/L)
Trial sites (1)
Facility
City
Region
Status
Department of Endocrinology
Aalborg
North Jutland
Recruiting
More Aalborg University Hospital trials in Denmark
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.